Phase 4
N=38
Time to Protection and Adherence Requirements of Raltegravir With or Without Lamivudine in Protection From HIV Infection
Hiv
Bottom Line
View on ClinicalTrials.gov: NCT03205566 ↗Enrolled (actual)
38
Serious AEs
0.0%
Results posted
Feb 2021
Primary outcome: Primary: The Level of Raltegravir Alone or Raltegravir /Lamivudine Required in the Plasma, Vagina and Rectum for 100% ex Vivo Protection From HIV — NA; 669.90; 265.10; 979.8 ng/mL
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 4
- Interventions
- Raltegravir 400Mg Tab (Drug); Lamivudine 150Mg Tablet (Drug)
- Age
- Adult · 18+ yrs
- Sex
- All
- Sponsor
- Guy's and St Thomas' NHS Foundation Trust
- Primary completion
- Sep 2018
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY The Level of Raltegravir Alone or Raltegravir /Lamivudine Required in the Plasma, Vagina and Rectum for 100% ex Vivo Protection From HIV |
NA; 669.90; 265.10; 979.8; 669.90; 265.10 | — |
| SECONDARY The Time From First Dose of Drug to Maximum Mucosal ex Vivo Protection From HIV. |
3; 2; 2; 2; 2.67; 3 | — |
| SECONDARY Number of Adverse Events Based on PE, Blood Test and Event Reporting on Raltegravir Based PrEP, in HIV Negative Individuals |
12; 15 | — |
| SECONDARY The Time to Cessation of Mucosal ex Vivo Protection From HIV After Stopping ART at Steady State. |
3.33; NA; NA; NA; 4; NA | — |
Summary
This study evaluates whether a 7-day course of Raltegravir 400mg bd or Raltegravir 400mg/lamivudine 150mg bd can prevent HIV from infecting genital tissue and will relate the level of drug in the blood to the level of drug in genital tissue and to the ability to of HIV to infect genital tissue. As well as determining whether these regimes can provide ex vivo protection against HIV, this study will also determine speed to provision of protection and a 48 hour PK/PD decay profile of Raltegravir following drug cessation after attaining steady state concentrations. The results will also inform all future HIV pre-exposure prophylaxis studies of Raltegravir and form the basis for large scale clinical trials without the need for tissue sampling. To date, efficacy studies assessing PrEP regimens have utilized HIV-acquisition endpoints with the consequence being such studies are required to be large in subject number in order to power observations. In addition the study will provide for the first time data on HIV protection rather than just Raltegravir drug levels in tissue, and allow assessment of the possibility of Raltegravir being used as an intermittent dosing regimen in PrEP.
Eligibility Criteria
Inclusion Criteria
- The ability to understand and sign a written informed consent form prior to participation in any screening procedures and must be willing to comply with all trial requirements.
- Male or non-pregnant, non-lactating females
- Age between 18 to 60 years, inclusive.
- Body Mass Index (BMI) of 16 to 35 kg/m2, inclusive.
- Negative antibody/antigen combined test for HIV.
- Absence of any significant health problems (in the opinion of the investigator) on the basis of the screening procedures; including medical history, physical examination, vital signs.
- Women participating in sexual intercourse that could result in pregnancy -must use an adequate form of contraception throughout the study and for two weeks after the study. This includes intrauterine device, condoms, anatomical sterility in self or partner. Oral hormonal methods and implant contraceptives are allowed but only in combination with the additional protection of a barrier method.
- Female participants may not use any vaginal products or objects or have vaginal sex for 48 hours before and after the collection of vaginal fluid and vaginal biopsies. This list includes tampons, female condoms, cotton wool, rags, diaphragms, cervical caps (or any other vaginal barrier method),douches, lubricants, vibrators/dildos, and drying agents.
- Males participating in sexual intercourse that could result in pregnancy must use condoms during the duration of the study.
- Men and women cannot use anal products or objects including but not exclusive to douches, lubricants and vibrators/dildos, butt plugs or urethral sounds or have receptive anal intercourse for 48 hours before and after the collection of rectal biopsies.
- Willing to abstain from multivitamins and antacids for the study duration.
Exclusion Criteria
- Any significant acute or chronic medical illness.
- Evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs or clinical laboratory determinations.
- Positive blood screen for syphilis, hepatitis B (HBs Ag) and/or C antibodies.
- Positive blood screen for HIV antibodies.
- Positive screen for sexually transmitted infections at screening visit
- High-risk behaviour for HIV infection which is defined as having one of the following within three months before trial day 0 (first dose): had unprotected vaginal or anal sex with a known HIV infected person or a casual partner. engaged in sex work for money or drugs. acquired a bacterial sexually transmitted disease in the past 3 months. having a known HIV positive partner either currently or in the previous six months Females who are pregnant or breast-feeding.
- Clinically significant laboratory abnormalities (according to normal range as defined by central laboratory).
- Participation in a clinical trial of an Investigational product within 1 month of planned baseline enrolment in this study.
- Ingestion of H2 receptor antagonists or proton pump inhibitor drugs in the preceding 14 days
- Current of planned use of anti-epileptics
Data sourced from ClinicalTrials.gov (NCT03205566). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.